<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101601192</journal-id>
<journal-id journal-id-type="pubmed-jr-id">41009</journal-id>
<journal-id journal-id-type="nlm-ta">Curr Genet Med Rep</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr Genet Med Rep</journal-id>
<journal-title-group>
<journal-title>Current genetic medicine reports</journal-title>
</journal-title-group>
<issn pub-type="epub">2167-4876</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30393588</article-id>
<article-id pub-id-type="pmc">6208355</article-id>
<article-id pub-id-type="doi">10.1007/s40142-018-0138-9</article-id>
<article-id pub-id-type="manuscript">NIHMS964919</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Mitochondrial Disease: Advances in clinical diagnosis, management, therapeutic development, and preventative strategies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Muraresku</surname>
<given-names>Colleen C.</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McCormick</surname>
<given-names>Elizabeth M.</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Falk</surname>
<given-names>Marni J.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="author-notes" rid="FN1">*</xref>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Division of Human Genetics, Childrenâ€™s Hospital of Philadelphia, Philadelphia, PA 19104, USA</aff>
<aff id="A2">
<label>2</label>Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Corresponding author Marni J. Falk, MD, ARC 1002c, 3615 Civic Center Blvd, Philadelphia, PA 19104, +1-215-590-4564 (phone), +1-267-426-2876 (fax), <email>falkm@email.chop.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p>
<bold>Conflict of Interest</bold>
</p>
<p>Marni J. Falk reports other from REATA Pharmaceuticals, grants, personal fees and other from Stealth Pharmaceuticals, other from United Mitochondrial Disease Foundation, other from GENESIS, grants and other from Raptor Pharmaceuticals, outside the submitted work. The other authors declare that they have no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>3</day>
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>2</day>
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>6</month>
<year>2019</year>
</pub-date>
<volume>6</volume>
<issue>2</issue>
<fpage>62</fpage>
<lpage>72</lpage>
<!--elocation-id from pubmed: 10.1007/s40142-018-0138-9-->
<self-uri xlink:href="https://link.springer.com/article/10.1007/s40142-018-0138-9"></self-uri>
<abstract>
<sec id="S1">
<title>Purpose of review</title>
<p id="P1">Primary mitochondrial disease encompasses an impressive range of inherited energy deficiency disorders having highly variable molecular etiologies as well as clinical onset, severity, progression, and response to therapies of multi-system manifestations. Significant progress has been made in primary mitochondrial disease diagnostic approaches, clinical management, therapeutic options, and preventative strategies that are tailored to major mitochondrial disease phenotypes and subclasses.</p>
</sec>
<sec id="S2">
<title>Recent findings</title>
<p id="P2">The extensive phenotypic pleiotropy of individual mitochondrial diseases from an organ-based perspective is reviewed. Improved consensus on standards for mitochondrial disease patient care are being complemented by emerging therapies that target specific molecular subtypes of mitochondrial disease. Reproductive counseling options now include preimplantation genetic diagnosis at the time of in vitro fertilization for familial mutations in nuclear genes and some mtDNA disorders. Mitochondrial replacement technologies have promise for some mtDNA disorders, although practical and societal challenges remain to allow their further research analyses and clinical utilization.</p>
</sec>
<sec id="S3">
<title>Summary</title>
<p id="P3">A dramatic increase has occurred in recent years in the recognition, understanding, treatment options, and preventative strategies for primary mitochondrial disease.</p>
</sec>
</abstract>
<kwd-group>
<kwd>mitochondrial disease</kwd>
<kwd>diagnosis</kwd>
<kwd>treatment</kwd>
<kwd>prevention</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>